A multi-institutional study led by UNC Lineberger Comprehensive Cancer Center researchers found that diagnostic mammography results vary across racial and ethnic groups, with the rate of diagnostic accuracy highest in non-Hispanic white women and lowest in Hispanic women.
Results from the ELIANA pivotal clinical trial showed the long-term benefit of Kymriah (tisagenlecleucel) in children and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, with a maximum survival follow-up of 5.9 years.
Five-year follow-up results from the phase III CLL14 trial demonstrated that over 60% of patients with previously untreated chronic lymphocytic leukemia who had received one-year fixed-duration combination treatment of Venclyxto/Venclexta (venetoclax) plus Gazyva (obinutuzumab) continued to show longer progression-free survival and higher rates of undetectable minimal residual disease after four years off treatment.
The ongoing, open-label, single-arm, pivotal phase II FIREFLY-1 clinical trial, evaluating DAY101 (tovorafenib) as once-weekly monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma, yielded positive initial data from the first 22 patients enrolled.
NXP900 yielded positive data in a preclinical xenograft model of group 4 medulloblastoma.
SomaLogic and OncoHost signed a licensing agreement, through which OncoHost will license SomaLogic’s SomaScan Platform to develop proteomics tests for its PROphet diagnostic system, designed to predict patients’ response to immunotherapy treatments and provide strategies to overcome treatment resistance.
The University of Texas MD Anderson Cancer Center, Invectys Inc., and the Cell Therapy Manufacturing Center, a joint venture between MD Anderson and National Resilience Inc., announced a strategic collaboration to jointly develop a process for human leukocyte antigen-G targeted CAR T-cell therapy for solid tumors.
The plenary session at the ASCO 2022 annual meeting saw that rarest of things at a scientific conference: a standing ovation.
All fourteen rectal cancer patients in a small phase II study of dostarlimab, an anti-PD-1 monoclonal antibody, saw their cancer completely disappear—with no progression or recurrence at follow-up six to 25 months later. None of the patients required further chemotherapy, radiation, or surgery.
NCI must make a bigger investment in new cancer therapies and expand the clinical trials system that tests them, the institute’s Acting Director Douglas Lowy said in his remarks at the American Society of Clinical Oncology annual meeting June 4.
